TCRT NASDAQ
Alaunos Therapeutics, Inc.
1W: -24.8%
1M: -50.9%
3M: -61.9%
YTD: -75.0%
1Y: -66.9%
3Y: -95.9%
5Y: -99.7%
$0.82
-0.10 (-10.87%)
Weekly Expected Move ±20.5%
$0
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
7 relationships7
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2022-03-17
Earliest Filing
2025-06-10
Latest Filing
partner: 4
investor: 3
Counterparties (Filed by TCRT)
7 relationshipsCompanies named in TCRT's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Mast Hill Fund, L.P. | — | investor | Received a warrant to purchase 79,900 shares of common stock and entered into an amendment regarding warrant terms. | 2025-06-10 | View |
| Mast Hill Fund, L.P. | — | investor | Committed to purchase up to $25.0 million of the Company's common stock under an equity purchase agreement. | 2025-05-23 | View |
| Watermill Asset Management | — | investor | Purchased $500,000 of Series A-1 Convertible Preferred Stock in a private placement. | 2025-04-14 | View |
| Precigen, Inc. | PGEN | partner | Entered into an Amended and Restated Exclusive License Agreement with Alaunos Therapeutics, Inc. | 2023-04-04 | View |
| Precigen, Inc. | PGEN | partner | Cooperative Research and Development Agreement partner | 2022-06-27 | View |
| National Cancer Institute | — | partner | Cooperative Research and Development Agreement partner | 2022-03-17 | View |
| Precigen, Inc. | PGEN | partner | Cooperative Research and Development Agreement partner | 2022-03-17 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-22 | Material Agreement; Other Events; Exhibits | Agreement | View |
| 2026-09-17 | Bylaws Amendment | View | |
| 2026-06-29 | Other Events; Exhibits | View | |
| 2026-05-26 | Other Events; Exhibits | View | |
| 2026-05-18 | Other Events; Exhibits | View | |
| 2026-04-15 | Delisting Notice | View | |
| 2026-03-02 | Other Events; Financial Statements and Exhibits | View | |
| 2026-01-08 | Termination of Material Definitive Agreement; Material Modification to Rights of Security Holders; O | View | |
| 2025-12-23 | Other Events | View | |
| 2025-08-20 | Other Events | View | |
| 2025-07-22 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-07-17 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-07-10 | Material Modification to Rights of Security Holders; Submission of Matters to a Vote of Security Hol | View | |
| 2025-07-02 | Notice of Delisting or Transfer; Departure/Election of Directors; Appointment of Officers | View | |
| 2025-06-26 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Material Modifica | Agreement | View |
| 2025-06-26 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
| 2025-06-10 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Financial Stateme | Agreement | View |
| 2025-05-23 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Financial Stateme | Agreement | View |
| 2025-04-18 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-04-15 | Departure/Election of Directors; Appointment of Officers | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR